CAS: 1069-79-0; (2R)-3-(((2-Aminoethoxy)(Hydroxy)Phosphoryl)Oxy)Propane-1,2-Diyl Distearate

相似化合物

923-61-5 998-07-2 4004-05-1

上下游产品

二油酰基 L-α-磷脂酰乙醇胺 1,2-Dioleoyl-Sn-Glycero-3-Phosphoethanolamine 01/05/4004
Dioleoyl Phosphatidylethanolamine 20707-71-5
1,2-Distearoyl-Sn-Glycero-3-Phosphoric Acid 17966-16-4
Octadecanoic Acid (R)-2-[(2-Tert-Butoxycarbonylamino-Ethoxy)-Hydroxy-Phosphoryloxy]-1-Octadecanoyloxymethyl-Ethyl Ester 115265-94-6
N-Trityl-O-(1,2-Dioctadecanoyl-Sn-Glycero-3-Phosphoryl)-Ethanolamin 26531-41-9
(2S)-3-羟基-1,2-丙烷二基二硬脂酸酯 1,2-Distearoyl-Sn-Glycerol 10567-21-2

(2S)-3-羟基-1,2-丙烷二基二硬脂酸酯置于1H-1,2,3-三氮唑,1,8-二氮杂双环[5.4.0]十一碳-7-烯体系中,用 二氯甲烷 用作溶剂,化学反应 5.0H,反应生成1,2二硬酯酸-3磷脂酰乙醇胺
参考文献:一种二酰基磷脂酰乙醇胺的制备方法
标题:一种二酰基磷脂酰乙醇胺的制备方法
摘要:本发明提供了一种二酰基磷脂酰乙醇胺的制备方法,包括下列步骤:(1)溶剂和有机碱/无机碱的作用下,式i化合物和磷试剂发生取代反应,生成式a中间体1;(2)同一反应体系中,中间体1在有机碱/无机碱的存在下,与2‑(N‑芴甲氧羰基氨基)乙醇或n‑boc保护的乙醇胺发生取代反应,生成式b中间体2;(3)同一反应体系中,中间体2在氧化剂作用下氧化反应,生成式ii化合物;(4)式ii化合物在溶剂,碱的作用下,磷脂头基发生水解,得到式iii化合物.本发明的优点在于:本发明只需通过两步合成就可得到目标产物,且方法条件易控,后处理简单,副反应少,收率高,符合工业化生产的要求.

专利信息

专利号:US-2025049961-A1
优先权日:2021-12-23
标题 :Scalable and high-purity cell-free synthesis of closed-ended dna vectors
发明人：MONDS RUSSELL; CIPI JORIS; BLACKSTOCK DANIEL JASON; DURANT JOHN CHESTER
权利人:GENERATION BIO CO
摘要:This disclosure provides methods for scalable and high-purity cell-free synthesis of DNA vectors, particularly closed-ended DNA vectors (e.g., ceDNA vectors) having linear and continuous structure for delivery and expression of a transgene. The cell-free synthesis includes digesting a double-stranded DNA construct with at least one restriction endonuclease that is capable of cleaving the construct at cleavage sites, which are distinct from the recognition sites, to release an insert having unique overhangs that regulate the high specificity of the subsequent ligation reaction. The insert is then ligated with inverted terminal repeat (ITR) oligonucleotides to form the closed-ended DNA vector. Corresponding DNA vectors prepared by these methods and related products as well other base and intermediate vectors and constructs associated with the methods are also provided in this disclosure.

专利号:US-12383499-B2
优先权日:2018-01-01
标题:Scale up synthesis of silicasome nanocarriers
发明人：NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
权利人:UNIV CALIFORNIA
摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

专利号:US-12208146-B2
优先权日:2018-11-19
标 题 :Reconstituted HDL nanoparticles for delivery of radioactive agents and uses thereof
发明人：LACKO ANDRAS G; PROKAI LASZLO; ISAAC-OLIVÉ KEILA
权利人:UNIV OF NORTH TEXAS HEALTH SCIENCE CENTER; THE AUTONOMOUS UNIV OF THE STATE OF MEXICO
摘要:Despite the widespread use of nanotechnology in radio-imaging applications, lipoprotein based delivery systems received only limited attention so far. The subject application provides for the synthesis of a novel hydrophobic radio-imaging tracer. This tracer, comprising a hydrazinonicotinic acid (HYNIC)-N-dodecylamide and 99mTc conjugate can be encapsulated into rHDL nanoparticles (NPs). These rHDL NPs can selectively target the Scavenger Receptor type B1 (SR-B1) that is overexpressed on most cancer cells due to excess demand for cholesterol for membrane biogenesis and thus can target tumors in-vivo. Details of the tracer synthesis, characterization of rHDL/tracer complex, in-vitro uptake, stability studies and in-vivo application of this new radio-imaging approach are provided.

专利号:US-12442015-B2
优先权日:2018-01-19
标 题:Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors
发明人：ALKAN OZAN; KOTIN ROBERT MICHAEL; STANTON MATTHEW; KERR DOUGLAS ANTHONY; PELLETIER CAROLYN
权利人:GENERATION BIO CO
摘要:The application describes methods for synthetic synthesis and cell-free synthesis of DNA vectors, particularly closed-ended DNA vectors (e.g., ceDNA vectors) having linear and continuous structure for delivery and expression of a transgene. The present invention relates to an in vitro process for production of closed-ended DNA vectors, corresponding DNA vector products produced by the methods and uses thereof, and oligonucleotides and kits useful in the process of the invention. DNA vectors produced using the methods described herein are free from unwanted side effects due to contaminants introduced during production in cell lines, for example, bacterial or insect cell lines. Further provided herein are methods and cell lines for reliable gene expression in vitro, ex vivo and in vivo using the ceDNA vectors synthesized using the methods herein.

专利号:US-2022280429-A1
优先权日:2021-03-03
标 题:Tunable leukocyte-based biomimetic nanoparticles and methods of use
发明人：ZINGER ASSAF YOSEF; TARABALLI FRANCESCA
权利人:METHODIST HOSPITAL
摘要:Disclosed are liposomal formulations and biomimetic proteolipid nanoparticles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. Leukocyte-based biomimetic nanoparticles are disclosed that incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here it is shown that, while increasing the protein:lipid ratio to a maximum of 1:20 (wt./wt.) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. The combined use of a microfluidic, bottom-up approach, and the tuning of key synthesis parameters enabled the synthesis of reproducible, biomimetic nanoparticles for the improved targeted nanodelivery of a variety of inflammatory-based conditions, including particular cancers such as human breast cancer, and TNBC, in particular.

专利号:WO-2022227554-A1
优先权日:2021-04-30
标题 :Larotaxel-fatty alcohol small molecule prodrug and construction of self-assembling nanoparticle thereof
发明人：LUO CONG; WANG YONGJUN; YANG JINCHENG; MA HONGDA; SUN JIN; HE ZHONGGUI; FENG YAO; MA ZHINING
权利人:SUZHOU YUTAI PHARMACEUTICAL TECH CO LTD
摘要:The synthesis of a larotaxel-fatty alcohol small molecule prodrug with a tumor reduction response characteristic and the construction of a self-assembling nanoparticle, and the use thereof in the preparation of a drug delivery system. Provided is a larotaxel-stearyl alcohol small molecule prodrug, which is prepared into a larotaxel-fatty alcohol prodrug nanoparticle. The larotaxel-fatty alcohol prodrug nanoparticle can be a non-PEGylated larotaxel-fatty alcohol prodrug nanoparticle, a PEG-modified larotaxel-fatty alcohol prodrug nanoparticle, a drug-loaded larotaxel-fatty alcohol prodrug nanoparticle, and an active targeting larotaxel-fatty alcohol prodrug nanoparticle. The larotaxel-fatty alcohol prodrug has few synthetic steps, a simple process, reduced synthesis costs, a high yield and easy purification, and the nanoparticle formed by the self-assembly of the larotaxel-fatty alcohol small molecule prodrug has an ultra-small particle size, which reduces the toxicity and side effects while improving the curative effect of larotaxel.